Victor Perez Quinones, MD
Cornea and External Diseases Specialist · Durham, NCNPI 1790714327
Payments from drug & device makers
Across 226 payments — averaging $4375.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon Research LLC$665K
- Novartis$171K
- Kala Pharmaceuticals, Inc.$51K
- Dompe US, Inc.$34K
- Dompe Farmaceutici S.p.a.$16K
- Quidel Corporation$9K
- plus $43K from 19 others
Across 2 payments — averaging $273.99 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Dompe US, Inc.$548
What the payments were for
- Consulting fees$146,78882%
- Speaking & faculty fees$14,0008%
- Travel & lodging$6,6754%
- Food & beverage$11,4686%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon Research LLC | 11 | $665,128 |
| Novartis | 22 | $171,357 |
| Kala Pharmaceuticals, Inc. | 19 | $50,505 |
| Dompe US, Inc. | 41 | $33,695 |
| Dompe Farmaceutici S.p.a. | 11 | $16,169 |
| Quidel Corporation | 13 | $8,958 |
| Alcon | 12 | $5,285 |
| Regeneron | 3 | $5,154 |
| Mallinckrodt Hospital Products Inc. | 18 | $4,500 |
| Sun Pharmaceutical Industries Inc. | 8 | $3,934 |
| Bausch & Lomb Americas Inc. | 17 | $3,791 |
| Biocryst Pharmaceuticals, Inc. | 4 | $3,717 |
| Oyster Point Pharma, Inc. | 6 | $3,062 |
| Shire North American Group Inc | 2 | $2,874 |
| Sight Sciences, Inc. | 8 | $2,439 |
| Tarsus Pharmaceuticals, Inc. | 2 | $2,021 |
| Ocular Therapeutix, Inc. | 1 | $1,950 |
| AbbVie(2 entities) | 3 | $1,620 |
| Thea Pharma Inc. | 10 | $757 |
| Tearlab Corp | 3 | $707 |
| Harrow Eye, LLC | 4 | $464 |
| Eyepoint US, Inc. | 3 | $339 |
| Mallinckrodt Enterprises LLC | 3 | $284 |
| Ortho-clinical Diagnostics, Inc. | 1 | $123 |
| Aerie Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EYSUVIS$40,158
- AcrySof$13,300
- XIIDRA$11,522
- InflammaDry$7,748
- Oxervate$7,023
- INVELTYS$5,378
- ACTHAR$4,340
- CEQUA$3,744
- TYRVAYA$2,990
- TearCare SmartLid$2,123
- TEARCARE(TM) (2.2) SYSTEM KIT$2,123
- DEXTENZA$1,950
- Eye Health$1,362
- MIEBO$721
- TearLab Osmolarity System$610
- VYZULTA$289
- IYUZEH$254
- YUTIQ$240
- VEVYE$150
- enVista MX60 IOL$149
How this compares
Too few cornea and external diseases specialist providers in North Carolinato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 16 | $17,472 |
| Prednisolone Acetate | 44 | $2,115 |
| MoxifloxacinMoxifloxacin Hcl | 25 | $399 |
| Prednisone | 16 | $158 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis | $1,620 | $17,47216 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few cornea and external diseases specialist providers in North Carolinaon file to place this against a meaningful peer group, so we don't.
Other cornea and external diseases specialist in Durham
- Lloyd WilliamsDurham$7K
- Yun Bo TianDurham$4K
- Michelle KimDurham$424
- Adam BennettRaleigh$5K
- Sara SpyrisWinston Salem$2K
- Brent HoffmanRaleigh$2K
- Anthony TangWilmington$1K
- Patricia SmithRaleigh$323
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.